MARKET

ADPT

ADPT

Adaptive Biotechnologies
NASDAQ
7.35
+0.50
+7.30%
Opening 12:32 09/30 EDT
OPEN
6.84
PREV CLOSE
6.85
HIGH
7.43
LOW
6.84
VOLUME
263.66K
TURNOVER
1.11M
52 WEEK HIGH
37.55
52 WEEK LOW
5.96
MARKET CAP
1.05B
P/E (TTM)
-4.4812
1D
5D
1M
3M
1Y
5Y
Institutional owners may consider drastic measures as Adaptive Biotechnologies Corporation's (NASDAQ:ADPT) recent US$104m drop adds to long-term losses
Every investor in Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) should be aware of the most powerful shareholder...
Simply Wall St. · 09/15 10:48
BRIEF-Adaptive Biotech Announces Non-Dilutive Royalty Financing With Orbimed For Up To $250 Mln
BRIEF-Adaptive Biotech Announces Non-Dilutive Royalty Financing With Orbimed For Up To $250 Mln
Reuters · 09/12 12:41
Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing With OrbiMed For Up To $250M
Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that translates the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today
Benzinga · 09/12 12:31
Adaptive Biotechnologies Gets Up to $250 Million Non-Dilutive Royalty Financing With OrbiMed
Adaptive Biotechnologies Gets Up to $250 Million Non-Dilutive Royalty Financing With OrbiMed
MT Newswires · 09/12 10:37
Adaptive Biotechnologies to Participate in the Morgan Stanley Global Healthcare Conference
SEATTLE, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products ...
GlobeNewswire · 09/02 12:00
Cathie Wood Adds Over $1.7M In Teladoc Shares A Day After Report Of Amazon Winding Down Its Telehealth Service
Cathie Wood-led Ark Investment Management loaded up on 50,263 shares of Teladoc Health Inc (NYSE: TDOC), via the firm’s ARK Genomic Revolution ETF (NYSE: ARKG), valued at over $1.7 mi
Benzinga · 08/26 10:00
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
Upgrades
Benzinga · 08/25 14:34
Credit Suisse Initiates Coverage On Adaptive Biotechnologies with Underperform Rating, Announces Price Target of $8
Credit Suisse analyst Dan Leonard initiates coverage on Adaptive Biotechnologies (NASDAQ:ADPT) with a Underperform rating and announces Price Target of $8.
Benzinga · 08/25 13:37
More
About ADPT
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform combines a suite of chemistry, biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its commercial research products include immunoSEQ and immunoSEQ T-MAP. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). Its clonoSEQ diagnostic test detects and monitors the number of cancer cells that are present in a patient’s body during and after treatment, known as minimal residual disease (MRD). It uses its T cell receptor (TCR)-Antigen Map to develop research solutions and diagnostic products, such as immunoSEQ T-MAP and T-Detect. It also focuses on developing immune-mediated therapies in oncology and other disease areas.

Webull offers kinds of Adaptive Biotechnologies Corp stock information, including NASDAQ:ADPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADPT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADPT stock methods without spending real money on the virtual paper trading platform.